Karyopharm Therapeutics | KPTI - Equity Capital And Reserves


Karyopharm Therapeutics reported $-292.93M in Equity Capital and Reserves for its fiscal quarter ending in December of 2025.





Equity Capital And Reserves Change Date
AbbVie USD -6.66B 3.39B Mar/2026
Abbott USD 52.06B 69M Mar/2026
Amgen USD 9.19B 532M Mar/2026
AstraZeneca USD 47.33B 1.33B Mar/2026
BioCryst Pharmaceuticals USD -553.84M 434.69M Mar/2026
Bristol-Myers Squibb USD 20.07B 1.6B Mar/2026
Eli Lilly USD 31.2B 4.66B Mar/2026
Enanta Pharmaceuticals USD 126.59M 61.87M Dec/2025
GlaxoSmithKline GBP 17.42B 1.05B Mar/2026
Incyte USD 5.62B 455.37M Mar/2026
J&J USD 81.19B 358M Mar/2026
Karyopharm Therapeutics USD -292.93M 23.67M Dec/2025
MacroGenics USD 21.2M 34.39M Mar/2026
Merck USD 45.88B 6.73B Mar/2026
Nektar Therapeutics USD 89.83M 4.75M Dec/2025
Novartis USD 38.93B 7.2B Mar/2026
Novartis USD 46.13B 1.8B Dec/2025
Pfizer USD 90.1B 3.63B Mar/2026
Regeneron Pharmaceuticals USD 31.42B 166.7M Mar/2026
Roche Holding CHF 33.8B 758M Dec/2025
Sangamo BioSciences USD 19.6M 14.7M Jun/2025
Takeda JPY 7.77T 129.5B Mar/2026
Tectonic Therapeutic USD 230.42M 20.91M Mar/2026
TG Therapeutics USD 583.13M 64.89M Mar/2026
Ultragenyx Pharmaceutical USD -236M 156M Mar/2026
Xencor USD 515.63M 119.95M Mar/2026